The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Arvinas Holding, a preclinical biotech developing protein degradation therapies for advanced cancers, raised $120 million by offering 7.5 million shares at $16, the high end of the $14 to $16 range. The company raised $20 million more than it had planned by...read more
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Arvinas, a preclinical biotech developing protein degradation therapies for advanced cancers, announced terms for its IPO on Friday. The New Haven, CT-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: 12 IPOs wrap up active third quarter as SurveyMonkey pops 34%
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. Not surprising, SurveyMonkey (SVMK) was the week's top performer,...read more
Cancer biotech Arvinas prices upsized IPO at $16, the high end of the range
Arvinas Holding, a preclinical biotech developing protein degradation therapies for advanced cancers, raised $120 million by offering 7.5 million shares at $16, the high end of the $14 to $16 range. The company raised $20 million more than it had planned by...read more
US IPO Week Ahead: 13 IPOs close out 3rd quarter with biotechs, China and SurveyMonkey
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and...read more
Preclinical cancer biotech Arvinas sets terms for $100 million IPO
Arvinas, a preclinical biotech developing protein degradation therapies for advanced cancers, announced terms for its IPO on Friday. The New Haven, CT-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16....read more